St. Jude Medical Inc. said Thursday European Union regulators approved its Ensite Contact technology, which is designed to improve procedures used in treatment of a serious heart condition.
St. Jude said Ensite Contact is a diagnostic system of ablation catheters, hardware and software that can give physicians greater control during cardiac ablation procedures for the treatment of atrial fibrillation. The catheters are used to destroy small amounts of diseased heart tissue, allowing the heart to function better.
Ensite Contact’s software measures exactly how much contact the tip of the catheter is making with heart tissue, the company said.
Atrial fibrillation is a disorder in which the heart’s upper chambers beat rapidly and ineffectively.
St. Jude shares rose 11 cents to $37.88 in morning trading.